Albert Einstein College of Medicine and Teva Pharmaceuticals, in collaboration with multiple international institutions, ...

ORLANDO -- New results from the randomized CAHtalyst trials shed light on the benefits of crinecerfont (Crenessity) for adult and pediatric patients with congenital adrenal hyperplasia (CAH), a rare ...

Quince Therapeutics advances Ataxia-Telangiectasia treatment with innovative AIDE platform, insider support, and NEAT Phase 3 ...

As such, the notion of a non-pharmacological, side-effect-free intervention — like an open-label placebo — is particularly attractive. The study also prompts a broader conversation about how ...

Data from an open-label trial showed that foralumab treatment eased fatigue and lessened disability for some people with ...

Open-label placebo studies show that participants ... but in how it invites us to harness the placebo effect as a tool for everyday change. References Benedetti, F. (2014). Placebo effects ...

Fremanezumab reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder.

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 ...

An open-label study of 12 individuals with severe treatment-resistant depression found that their symptoms significantly ...

If phase 3 trials of MM120 (lysergide d-tartrate) for anxiety and depression are successful, could the LSD-based drug become ...

Capricor officials said the company was prepared for the meeting and does not expect it to delay the FDA’s decision on the ...